Asker Healthcare Group (ASKER) Q3 2025 earnings summary

Executive summary

• Q3 2025 net sales rose 15% year-over-year to SEK 4,129m, with 5–6% organic growth and strong operational performance, especially in West and Central regions.

• Adjusted EBITA/EBITDA increased 25% to SEK 383m, with a margin of 9.3% on a rolling 12-month basis.

• Twelve acquisitions completed in 2025, adding SEK 2.2bn in sales and expanding into France and other European markets.

• Profit for Q3 was SEK 146m, up 80% year-over-year; EPS before and after dilution was SEK 0.37.

• The company remains focused on a dual growth strategy: organic expansion and M&A, with a robust pipeline.

Financial highlights

• Q3 adjusted EBITA/EBITDA reached SEK 383m (up 25%), margin 9.3%; net sales SEK 4,129m (up 15%).

• Cash flow from operating activities in Q3 was SEK 439m, nearly double the prior year.

• Net debt/EBITDA at 2.2x, within the 2–2.5x target range.

• Year-to-date adjusted EBITA up 18% to SEK 1,125m; nine-month net sales up 13% to SEK 12,111m.

• Q3 profit was SEK 146m (up 80%); EPS SEK 0.37.

Outlook and guidance

• Earnings growth target of over 15% per year is being exceeded, with 20% rolling 12-month growth.

• Management expects continued strong growth, driven by organic expansion and acquisitions, with a robust pipeline.

• Leverage expected to remain in the 2–2.5x range as M&A continues.

• No major defense project orders expected in Q4; potential for new orders in 2026.

• Positive outlook for Business Area North despite lower project-based sales; further contract opportunities anticipated.